Annual Operating Expenses
$38.07 M
-$280.00 K-0.73%
31 December 2023
Summary:
Galectin Therapeutics annual total operating expenses is currently $38.07 million, with the most recent change of -$280.00 thousand (-0.73%) on 31 December 2023. During the last 3 years, it has risen by +$14.63 million (+62.40%). GALT annual operating expenses is now -0.73% below its all-time high of $38.35 million, reached on 31 December 2022.GALT Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$9.07 M
-$2.23 M-19.71%
30 September 2024
Summary:
Galectin Therapeutics quarterly total operating expenses is currently $9.07 million, with the most recent change of -$2.23 million (-19.71%) on 30 September 2024. Over the past year, it has dropped by -$100.00 thousand (-1.09%). GALT quarterly operating expenses is now -19.71% below its all-time high of $11.29 million, reached on 30 June 2024.GALT Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -0.7% | -1.1% |
| 3 y3 years | +62.4% | +10.0% |
| 5 y5 years | +179.9% | +216.7% |
GALT Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -0.7% | +62.4% | -19.7% | +22.1% |
| 5 y | 5 years | -0.7% | +183.3% | -19.7% | +216.7% |
| alltime | all time | -0.7% | +1644.7% | -19.7% | +1443.7% |
Galectin Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $9.07 M(-19.7%) |
| June 2024 | - | $11.29 M(+17.0%) |
| Mar 2024 | - | $9.65 M(+0.9%) |
| Dec 2023 | $38.07 M(-0.7%) | $9.56 M(+4.3%) |
| Sept 2023 | - | $9.17 M(+1.8%) |
| June 2023 | - | $9.00 M(-12.9%) |
| Mar 2023 | - | $10.34 M(-2.7%) |
| Dec 2022 | $38.35 M(+27.1%) | $10.63 M(+30.9%) |
| Sept 2022 | - | $8.12 M(-15.9%) |
| June 2022 | - | $9.66 M(-2.7%) |
| Mar 2022 | - | $9.94 M(+33.8%) |
| Dec 2021 | $30.18 M(+28.7%) | $7.42 M(-9.9%) |
| Sept 2021 | - | $8.24 M(+0.6%) |
| June 2021 | - | $8.19 M(+29.7%) |
| Mar 2021 | - | $6.32 M(-19.3%) |
| Dec 2020 | $23.44 M(+74.5%) | $7.83 M(+32.2%) |
| Sept 2020 | - | $5.93 M(-2.9%) |
| June 2020 | - | $6.10 M(+70.3%) |
| Mar 2020 | - | $3.58 M(-30.9%) |
| Dec 2019 | $13.44 M(-1.2%) | $5.19 M(+81.2%) |
| Sept 2019 | - | $2.86 M(-5.2%) |
| June 2019 | - | $3.02 M(+27.6%) |
| Mar 2019 | - | $2.37 M(-20.7%) |
| Dec 2018 | $13.60 M(-16.3%) | $2.98 M(+11.4%) |
| Sept 2018 | - | $2.68 M(-28.7%) |
| June 2018 | - | $3.76 M(-10.0%) |
| Mar 2018 | - | $4.18 M(+76.1%) |
| Dec 2017 | $16.25 M(-24.4%) | $2.37 M(-46.2%) |
| Sept 2017 | - | $4.41 M(-2.2%) |
| June 2017 | - | $4.51 M(-8.7%) |
| Mar 2017 | - | $4.95 M(+7.5%) |
| Dec 2016 | $21.48 M(+7.0%) | $4.60 M(+1.4%) |
| Sept 2016 | - | $4.54 M(-18.0%) |
| June 2016 | - | $5.53 M(-18.8%) |
| Mar 2016 | - | $6.81 M(+45.5%) |
| Dec 2015 | $20.08 M(+30.1%) | $4.68 M(-20.6%) |
| Sept 2015 | - | $5.90 M(+26.7%) |
| June 2015 | - | $4.66 M(-3.8%) |
| Mar 2015 | - | $4.84 M(+29.6%) |
| Dec 2014 | $15.43 M(+27.5%) | $3.73 M(+7.4%) |
| Sept 2014 | - | $3.48 M(+3.0%) |
| June 2014 | - | $3.38 M(-30.3%) |
| Mar 2014 | - | $4.84 M(+72.8%) |
| Dec 2013 | $12.10 M(+22.3%) | $2.80 M(-20.9%) |
| Sept 2013 | - | $3.54 M(+39.2%) |
| June 2013 | - | $2.55 M(-20.6%) |
| Mar 2013 | - | $3.21 M(+34.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $9.90 M(-4.9%) | $2.38 M(-17.7%) |
| Sept 2012 | - | $2.90 M(+8.5%) |
| June 2012 | - | $2.67 M(+36.6%) |
| Mar 2012 | - | $1.95 M(-42.1%) |
| Dec 2011 | $10.41 M(+113.2%) | $3.37 M(+65.9%) |
| Sept 2011 | - | $2.03 M(-32.0%) |
| June 2011 | - | $2.99 M(+48.6%) |
| Mar 2011 | - | $2.01 M(+56.2%) |
| Dec 2010 | $4.88 M(-19.9%) | $1.29 M(+6.4%) |
| Sept 2010 | - | $1.21 M(-10.2%) |
| June 2010 | - | $1.35 M(+30.8%) |
| Mar 2010 | - | $1.03 M(-7.6%) |
| Dec 2009 | $6.09 M(+14.4%) | $1.12 M(-10.6%) |
| Sept 2009 | - | $1.25 M(-37.2%) |
| June 2009 | - | $1.99 M(+14.9%) |
| Mar 2009 | - | $1.73 M(+57.5%) |
| Dec 2008 | $5.33 M(-17.5%) | $1.10 M(+17.3%) |
| Sept 2008 | - | $939.00 K(-49.9%) |
| June 2008 | - | $1.87 M(+32.7%) |
| Mar 2008 | - | $1.41 M(+1.5%) |
| Dec 2007 | $6.46 M(-8.4%) | $1.39 M(+1.7%) |
| Sept 2007 | - | $1.37 M(-22.8%) |
| June 2007 | - | $1.77 M(-7.9%) |
| Mar 2007 | - | $1.92 M(+48.5%) |
| Dec 2006 | $7.05 M(+5.9%) | $1.30 M(-32.8%) |
| Sept 2006 | - | $1.93 M(-8.1%) |
| June 2006 | - | $2.10 M(+21.8%) |
| Mar 2006 | - | $1.72 M(-2.5%) |
| Dec 2005 | $6.66 M(-8.9%) | $1.77 M(+3.8%) |
| Sept 2005 | - | $1.71 M(-1.3%) |
| June 2005 | - | $1.73 M(+18.9%) |
| Mar 2005 | - | $1.45 M(-33.8%) |
| Dec 2004 | $7.30 M(+47.9%) | $2.19 M(+22.0%) |
| Sept 2004 | - | $1.80 M(+25.2%) |
| June 2004 | - | $1.44 M(-23.3%) |
| Mar 2004 | - | $1.87 M(+16.9%) |
| Dec 2003 | $4.94 M(+50.2%) | $1.60 M(+14.5%) |
| Sept 2003 | - | $1.40 M(+42.6%) |
| June 2003 | - | $981.90 K(+3.0%) |
| Mar 2003 | - | $953.10 K(-12.5%) |
| Dec 2002 | $3.29 M(+50.6%) | $1.09 M(+70.5%) |
| Sept 2002 | - | $639.00 K(-24.1%) |
| June 2002 | - | $841.50 K(+17.3%) |
| Mar 2002 | - | $717.20 K(-2.2%) |
| Dec 2001 | $2.18 M | $733.10 K(+15.3%) |
| Sept 2001 | - | $635.80 K(+8.3%) |
| June 2001 | - | $587.30 K |
FAQ
- What is Galectin Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Galectin Therapeutics?
- What is Galectin Therapeutics annual operating expenses year-on-year change?
- What is Galectin Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly operating expenses year-on-year change?
What is Galectin Therapeutics annual total operating expenses?
The current annual operating expenses of GALT is $38.07 M
What is the all time high annual operating expenses for Galectin Therapeutics?
Galectin Therapeutics all-time high annual total operating expenses is $38.35 M
What is Galectin Therapeutics annual operating expenses year-on-year change?
Over the past year, GALT annual total operating expenses has changed by -$280.00 K (-0.73%)
What is Galectin Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of GALT is $9.07 M
What is the all time high quarterly operating expenses for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly total operating expenses is $11.29 M
What is Galectin Therapeutics quarterly operating expenses year-on-year change?
Over the past year, GALT quarterly total operating expenses has changed by -$100.00 K (-1.09%)